BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 12131304)

  • 1. Biochemical disease-free survival in men younger than 60 years with prostate cancer treated with external beam radiation.
    Rosser CJ; Chichakli R; Levy LB; Kuban DA; Smith LG; Pisters LL
    J Urol; 2002 Aug; 168(2):536-41. PubMed ID: 12131304
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improved biochemical disease-free survival of men younger than 60 years with prostate cancer treated with high dose conformal external beam radiotherapy.
    Zelefsky MJ; Marion C; Fuks Z; Leibel SA
    J Urol; 2003 Nov; 170(5):1828-32. PubMed ID: 14532785
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hazard rates of disease progression after external beam radiotherapy for clinically localized carcinoma of the prostate.
    Rosser CJ; Levy LB; Kuban DA; Chichakli R; Pollack A; Lee A; Pisters LL
    J Urol; 2003 Jun; 169(6):2160-5. PubMed ID: 12771739
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Year of treatment as independent predictor of relapse-free survival in patients with localized prostate cancer treated with definitive radiotherapy in the PSA era.
    Kupelian P; Thames H; Levy L; Horwitz E; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A; Kuban D
    Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):795-9. PubMed ID: 15925452
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prostate specific antigen bounce after simultaneous irradiation for prostate cancer: the relationship to patient age.
    Critz FA; Williams WH; Levinson AK; Benton JB; Schnell FJ; Holladay CT; Shrake PD
    J Urol; 2003 Nov; 170(5):1864-7. PubMed ID: 14532794
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improved biochemical relapse-free survival with increased external radiation doses in patients with localized prostate cancer: the combined experience of nine institutions in patients treated in 1994 and 1995.
    Kupelian P; Kuban D; Thames H; Levy L; Horwitz E; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A
    Int J Radiat Oncol Biol Phys; 2005 Feb; 61(2):415-9. PubMed ID: 15667961
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prostate-specific antigen doubling time predicts clinical outcome and survival in prostate cancer patients treated with combined radiation and hormone therapy.
    Lee AK; Levy LB; Cheung R; Kuban D
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):456-62. PubMed ID: 15927415
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Perineural invasion affects biochemical recurrence-free survival in patients with prostate cancer treated with definitive external beam radiotherapy.
    Yu HH; Song DY; Tsai YY; Thompson T; Frassica DA; DeWeese TL
    Urology; 2007 Jul; 70(1):111-6. PubMed ID: 17656219
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of percent positive prostate biopsies and perineural invasion with biochemical outcome after external beam radiotherapy for localized prostate cancer.
    Wong WW; Schild SE; Vora SA; Halyard MY
    Int J Radiat Oncol Biol Phys; 2004 Sep; 60(1):24-9. PubMed ID: 15337536
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Permanent interstitial brachytherapy in younger patients with clinically organ-confined prostate cancer.
    Merrick GS; Butler WM; Wallner KE; Galbreath RW; Adamovich E
    Urology; 2004 Oct; 64(4):754-9. PubMed ID: 15491715
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Salvage prostate brachytherapy for localized prostate cancer failure after external beam radiation therapy.
    Lee HK; Adams MT; Motta J
    Brachytherapy; 2008; 7(1):17-21. PubMed ID: 18201939
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prostate-specific antigen control with low-dose adjuvant radiotherapy for high-risk prostate cancer.
    Macdonald OK; Lee RJ; Snow G; Lee CM; Tward JD; Middleton AW; Middleton GW; Sause WT
    Urology; 2007 Feb; 69(2):295-9. PubMed ID: 17320667
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prediagnosis prostate specific antigen velocity is associated with risk of prostate cancer progression following brachytherapy and external beam radiation therapy.
    Eggener SE; Roehl KA; Yossepowitch O; Catalona WJ
    J Urol; 2006 Oct; 176(4 Pt 1):1399-403. PubMed ID: 16952643
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lack of benefit of pelvic radiation in prostate cancer patients with a high risk of positive pelvic lymph nodes treated with high-dose radiation.
    Vargas CE; Galalae R; Demanes J; Harsolia A; Meldolesi E; Nürnberg N; Schour L; Martinez A
    Int J Radiat Oncol Biol Phys; 2005 Dec; 63(5):1474-82. PubMed ID: 15964706
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Conformal high dose rate brachytherapy improves biochemical control and cause specific survival in patients with prostate cancer and poor prognostic factors.
    Martinez A; Gonzalez J; Spencer W; Gustafson G; Kestin L; Kearney D; Vicini FA
    J Urol; 2003 Mar; 169(3):974-9; discussion 979-80. PubMed ID: 12576825
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pretreatment predictors of time to cancer specific death after prostate specific antigen failure.
    D'Amico AV; Cote K; Loffredo M; Renshaw AA; Chen MH
    J Urol; 2003 Apr; 169(4):1320-4. PubMed ID: 12629352
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patterns of local failure following prostate brachytherapy.
    Stone NN; Stock RG; White I; Unger P
    J Urol; 2007 May; 177(5):1759-63; duscussion 1763-4. PubMed ID: 17437808
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The long-term clinical impact of biochemical recurrence of prostate cancer 5 or more years after radical prostatectomy.
    Ward JF; Blute ML; Slezak J; Bergstralh EJ; Zincke H
    J Urol; 2003 Nov; 170(5):1872-6. PubMed ID: 14532796
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical results of combined treatment conformal high-dose-rate iridium-192 brachytherapy and external beam radiotherapy using staging lymphadenectomy for localized prostate cancer.
    Hiratsuka J; Jo Y; Yoshida K; Nagase N; Fujisawa M; Imajo Y
    Int J Radiat Oncol Biol Phys; 2004 Jul; 59(3):684-90. PubMed ID: 15183471
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lack of benefit from a short course of androgen deprivation for unfavorable prostate cancer patients treated with an accelerated hypofractionated regime.
    Martinez AA; Demanes DJ; Galalae R; Vargas C; Bertermann H; Rodriguez R; Gustafson G; Altieri G; Gonzalez J
    Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1322-31. PubMed ID: 16029788
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.